Alvogen opening biosimilars plant in Iceland

Biosimilars/News | Posted 17/06/2016 post-comment1 Post your comment

Iceland-based biopharmaceutical company Alvotech, a sister company of US generics company Alvogen, is set to open its state-of-the-art 11,800 square meter development and manufacturing facility for biosimilars in June 2016.

picture 120

Alvotech began construction on the purpose-built plant in the science park of the University of Iceland in Reykjavik back in November 2013 [1]. Iceland was chosen as a logical place for Alvogen’s biosimilars business, due to its favourable environment with a strong regulatory system, low operating costs, a great talent pool, high quality standards and a convenient geographical location between the European Union and the US that is within easy reach of the rest of the world. The new facility is expected to create around 200 jobs and will include 12 disposable bioreactors, along with filling and finishing capabilities for syringes and vials.

On 13 February 2014, Alvogen launched the infliximab biosimilar Inflectra in Central and Eastern Europe in collaboration with Hospira [2]. The company also has six of its own biosimilars in development and is investing over US$500 million in the development of its pipeline and its new development and manufacturing plant.

The company’s own biosimilars include versions of leading monoclonal antibody molecules, some of which are reported to be at an advanced development stage. Alvotech intends to bring the biosimilars to market by 2018.

Related articles
Pamplona investment group buys majority share in Alvolgen

Alvotech and Finesse enter into biosimilars collaboration

1. GaBI Online - Generics and Biosimilars Initiative. Alvotech invests US$250 million in biosimilars []. Mol, Belgium: Pro Pharma Communications International; [cited 2016 Jun 17]. Available from:
2. GaBI Online - Generics and Biosimilars Initiative. Alvogen launches infliximab biosimilar in Europe []. Mol, Belgium: Pro Pharma Communications International; [cited 2016 Jun 17]. Available from:

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2016 Pro Pharma Communications International. All Rights Reserved.

Source: Alvotech

comment icon Comments (1)
Post your comment
Posted 05/03/2023 by Narayan Yadav
Microbiology department

Any vacancies there for microbiology

Related content
EC approval of first ustekinumab biosimilar Uzpruvo
Biosimilars/News Posted 16/01/2024
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010